Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius Medical Care AG & Co. KGaA

Investor Presentation • Sep 11, 2008

165_ip_2008-09-11_45cca009-42b5-4235-bd5e-68e9aaf3bf06.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Fresenius Medical CareThe World's Leading Renal Therapy Company

UBS Best of Germany One-on-One Conference

New York, September 11, 2008

Safe Harbor Statement

This presentation includes certain forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. These and other risks and uncertainties are detailed in the Company's reports filed with the Securities and Exchange Commission and the German Exchange Commission "Deutsche Börse".

Agenda

1. Business Update

2. Financials and Outlook

3. Midterm Strategy

4. Attachments

Q2 2008 – Strong Quarter

R
e
v
e
n
u
e		 \$
2
6
6
5
m
,		 1
1
%
+
N
i
t
e
n
c
o
m
e		 \$
2
1
1
m		 1
8
%
+
E
i
h
a
r
n
n
g
s
p
e
r
s
a
r
e		 \$
0
7
1		 1
8
%
+

On track to achieve Full Year Guidance

despite:

  • EPO reimbursement below previous year
  • Heparin costs in North America significantly higher in the second half of 2008

Q2 2008 – Strong Organic Growth of 7%

Total Revenue Increased by 11% to \$ 2,665 m *

Dialysis Services - Global

Accelerated International Growth of 19% cc

\$
U
S
i
i
l
l
i
n
m
o
n
s
-		 Q
2
2
0
0
7		 Q
2
2
0
0
8		 G
h
t
r
o
w		 c
c
N
h
A
i
t
o
r
m
e
r
c
a		 1
4
9
9
,		 3
3
1
5
,		 2
%
A
d
j
d
f
h
l
f
h
f
i
b
i
t
t
t
u
s
e
o
r
e
s
a
e
o
e
p
e
r
u
s
o
n
u
s
n
e
s
s		 3
%
I
i
l
t
t
n
e
r
n
a
o
n
a		 2
9
6		 3
9
1		 3
2
%		 1
9
%
T
l
t
o
a		 1
7
9
6
,		 9
2
1
4
,		 7
%		 5
%
A
d
j
d
f
h
l
f
h
f
i
b
i
t
t
t
u
s
e
o
r
e
s
a
e
o
e
p
e
r
u
s
o
n
u
s
n
e
s
s		 8
%		 6
%

cc = constant currency

Strong Organic Revenue growth and improving Revenue per Treatment

Q
2
2
0
0
8		 T
l
t
o
a		 N
h
A
i
t
o
r
m
e
r
c
a		 I
i
l
t
t
n
e
r
n
a
o
n
a
O
i
h
t
r
g
a
n
c
r
e
v
e
n
u
e
g
r
o
w		 5
%
+		 3
%
+		 9
1
%
+
S
k
h
t
t
t
t
t
a
m
e
m
a
r
e
r
e
a
m
e
n
g
r
o
w		 2
4
%
+		 2
8
%
+		 9
7
%
+
R
t
t
t
e
v
e
n
u
e
p
e
r
r
e
a
m
e
n		 1)
\$
3
2
3		 \$
1
8
3
G
h
t
r
o
w		 0.
1
%
-		 1
0.
3
%
c
c
+
C
l
i
i
Q
2
2
0
0
8
n
c
s		 2
3
8
1
,		 6
1
4
7
,		 6
7
1
G
h
t
r
o
w		 5
%
+		 4
%
+		 7
%
+
Q
D
2
e
n
o
o
s
v
(
inc
lu
d
ing
d c
l
in
ics
)
m
an
ag
e		 2
6		 2
1		 1
4

1) including Mexico

cc = constant currency

Dialysis Services - United States

Epo Utilization and Dialysis Reimbursementdeveloping as Expected

Quality Outcomes - Global

Overall Strong Quality Performance Except for Hemoglobin

N
h
A
i
t
o
r
m
e
r
c
a		 E
M		 E
A
f
F
M
E
i
%
t
t
o
p
a
e
n
s		 Q
2
2
0
0
7		 Q
2
2
0
0
8		 Q
2
2
0
0
7		 Q
2
2
0
0
8
K
/
V
≥
1
2
t		 9
4
%		 9
5
%		 9
4
%		 9
5
%
H
l
b
i
d
l
≥
1
1
/
e
m
o
g
o
n
g		 8
1
%		 3
7
%		 7
2
%		 6
9
%
A
l
b
i
≥
3
5
/
d
l
u
m
n
g		 7
9
%		 8
0
%		 8
6
%		 8
5
%
P
h
h
3
d
l
5
5
5
/
t
o
s
p
a
e
m
g
-		 5
2
%		 5
5
%		 5
7
%		 6
0
%
H
i
l
i
i
d
t
t
o
s
p
a
z
a
o
n
a
y
s		 *
1
1
2		 *
0
1
5		 7
9		 8
0

* The hospitalization rates for the US reflects FMS adoption of CMS policy

Quality Outcomes - United States

EPO Utilization

Data Source: FMC-NA Clinical Data Warehouse and IRIS Data Warehouse - All FME U.S. clinics (including RCG legacy)10

Quality Outcomes - United States

Anemia Management

(3 months average)

11,8 11,9 11,9 11,9 11,6

g/dl

10

11

12

11,7

Q4 03 Q4 04 Q4 05 Q4 06 Q1 08

11,5

Dialysis Products - Global

Excellent External Product Revenue Growth

\$
U
S
i
i
l
l
i
n
m
o
n
s
-		 Q
2
2
0
0
7		 Q
2
2
0
0
8		 G
h
t
r
o
w		 c
c
T
l
t
o
a
r
e
e
n
e
v
u
(
i
l.
I
l
R
)
t
n
c
n
e
r
n
a
e
v
e
n
u
e		 7
9
9		 9
3
5		 1
9
%		 1
0
%
E
l
t
x
e
r
n
a
r
e
v
e
n
u
e		 6
0
9		 7
4
1		 2
2
%		 1
2
%
N
h
A
i
t
o
r
m
e
r
c
a		 1
6
1		 8
2
1		 1
3
%		 1
3
%
I
i
l
t
t
n
e
r
n
a
o
n
a		 4
4
8		 9
5
5		 2
5
%		 1
1
%

U.S. Legislative Update

Medicare Bill was passed on July 14, 2008

Key Dialysis components included are:

  • Composite rate increase of 1% per annum in 2009 and 2010
  • New law mandates a bundled payment rate at 98% of total nonbundled expenditures starting in 2011
  • •Providers may elect to voluntarily phase in over 3 years
  • Permanent market basket increase beginning in 2012, estimated approximately 2% per year
  • Extends authority for Medicare Advantage Special Needs Plan (MA-SNP) through 2011
  • Delays moratorium on new MA-SNP to 2010

Fresenius Medical Care – North America

Health Plan 2nd year results

I.V. Iron - North America

Focusing on further improving patient therapy and expanding market opportunities globally

Exclusive 10 year U.S. manufacturing and distribution sublicense agreement for Venofer® and next generation I.V. Iron product for dialysis stage V

Venofer® is the leading I.V. Iron product worldwide oTotal U.S. I.V. Iron purchases are ~ \$500 million

(Venofer® accounts for 55%)

I.V. Iron - International

Focusing on further improving patient therapy and expanding market opportunity in Europe and Latin America

  • Exclusive agreement with Galenica to commercialize I.V. Iron products Venofer®and Ferinject® for dialysis stage V patients
  • Total market for I.V. Iron in Europe, Middle East, Africa, and Latin America was more than \$120 million in 2007
  • o Commercialization expected to become effective – no later than January 1, 2009
  • oExpected 2010 annual sales to be about \$50 million

Highlights Q2

N
h
t
E
(
E
U
)

o
r
u
r
o
p
e
A
i
m
e
r
c
a

A
i
P
i
f
i
(
A
P
)
s
a
a
c
c
-
-
C
i
d
h
i
d
f
1
3
%
t
t
t
t
o
n
n
e
r
e
e
n
e
g
r
o
m
o
m
e
n
m
n
p
r
o
c
s
o
u
v
u
w
u
u

B
d
l
i
b
i
i
h
i
d
2
0
1
1
t
t
t
t
t
n
e
r
e
m
r
s
e
m
e
n
n
a
o
m
a
c
p
a
e
u
u
w
u
u

A
i
M
d
l
i
d
t
t
n
e
m
a
a
n
a
g
e
m
e
n
e
v
e
o
p
n
g
a
s
e
x
p
e
c
e

A
d
d
I
V
I
h
R
l
P
h
P
f
l
i
t
t
t
r
o
n
o
e
e
n
a
a
r
m
a
o
r
o
o
E
u
r
o
p
e
R
h
i
d
f
1
3
%
t
t
t
e
e
n
e
g
r
o
m
o
m
e
n
m
c
o
n
n
e
o
c
c
v
u
w
u
u

C
i
d
h
i
E
E
1
7
%
t
t
t
t
o
n
n
e
s
r
o
n
g
g
r
o
n
a
s
e
r
n
r
o
p
e
u
w
u
+

S
k
h
f
9
%
t
t
t
t
t
a
m
e
m
a
r
e
r
e
a
m
e
n
g
r
o
w
o

V
h
i
h
A
R
l
B
i
t
t
t
t
e
r
s
r
o
n
g
g
r
o
n
e
c
e
e
n
a
s
n
e
s
s
y
w
u
u
A
i
s
a
-
P
i
f
i
a
c
c
S
k
h
f
6
%
t
t
t
t
t
t
r
o
n
g
s
a
m
e
m
a
r
e
r
e
a
m
e
n
g
r
o
w
o

I
i
h
i
C
h
i
f
4
2
%
t
m
p
r
e
s
s
v
e
r
e
v
e
n
u
e
g
r
o
w
n
n
a
o
c
c

C
i
d
i
i
h
f
(
l.
J
)
3
8
%
t
t
o
n
n
e
m
p
r
e
s
s
e
r
e
e
n
e
g
r
o
o
c
c
e
c
a
p
a
n
u
v
v
u
w
x

S
L
h
f
h
i
h
f
d
i
l
F
X
a
u
n
c
o
n
e
w
g
p
e
r
o
r
m
a
n
c
e
a
y
z
e
r
-

cc= constant currency

Agenda

1. Business Update

2. Financials and Outlook

3. Midterm Strategy

4. Attachments

Profit & Loss

\$
U
S
i
i
l
l
i
n
m
o
n
s
-		 Q
2
2
0
0
7		 Q
2
2
0
0
8		 G
h
t
r
o
w
*
N
t
e
r
e
e
n
e
v
u		 2
4
0
4
,		 2
6
6
5
,		 1
1
%
O
i
i
(
E
B
I
T
)
t
p
e
r
a
n
g
n
c
o
m
e		 3
9
1		 2
9
4		 1
0
%
E
B
I
T
i
i
%
m
a
r
g
n
n		 1
6.
3		 1
6.
1
I
t
t
t
n
e
r
e
s
e
x
p
e
n
s
e
n
e
,		 9
2		 8
2
f
I
b
i
t
n
c
o
m
e
e
o
r
e
n
c
o
m
e
a
x		 2
9
9		 3
4
7		 1
6
%
I
T
n
c
o
m
e
a
x
e
x
p
e
n
s
e		 1
1
3		 2
9
1
T
t
a
x
r
a
e		 3
8
0
%		 3
7.
2
%
M
i
i
i
t
t
t
n
o
r
y
n
e
r
e
s		 7 7
N
i
t
e
n
c
o
m
e		 1
7
9		 2
1
1		 1
8
%

* 7% growth at constant currency, 7% organic growth

C
h
F
l
a
s
o
w
\$
U
S
i
i
l
l
i
n
m
o
n
s
-		 Q
2
2
0
0
7		 Q
2
2
0
0
8		 G
h
t
r
o
w
1)
N
h
i
d
d
b
i
i
i
i
t
t
t
t
e
c
a
s
p
r
o
v
e
y
o
p
e
r
a
n
g
a
c
v
e
s		 2
2
5		 2
0
9
f r
8
%
o
ev
en
ue		 (
)
7
%
1)
C
i
l
d
i
t
t
(
)
a
p
a
e
x
p
e
n
u
r
e
s
t
n
e		 (
)
1
3
0		 (
9
)
1
7
F
C
h
F
l
r
e
e
a
s
o
w		 9
5		 3
0		 (
6
9
%
)
1)
A
i
i
i
f
d
i
i
t
t
t
t
c
q
u
s
o
n
s
n
e
o
v
e
s
u
r
e
s
,		 2 (
5
8
)
F
C
h
F
l
r
e
e
a
s
o
w
f
i
i
i
t
t
a
e
r
a
c
q
s
o
n
s
u		 9
7		 (
)
2
8

1) A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

Debt and EBITDA Development

including non-cash charges

•

pf = pro forma excluding restructuring costs, in-process R&D and gain from the sale of dialysis clinics ltm = last twelve months cl = closing RCGA reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

Outlook 2008 - Confirmed

\$
U
S
i
i
l
l
i
n
m
o
n
s
-		 G
i
d
a
n
c
e
u
N
R
t
e
e
v
e
n
u
e
s		 \$
0
0
0
1
4
>
,
N
I
t
e
n
c
o
m
e		 \$
8
0
5
8
2
5
-
L
i
t
e
v
e
r
a
g
e
r
a
o
(
D
b
/
E
B
I
T
D
A
)
t
e		 2
8
<
C
i
l
E
d
i
t
t
a
p
a
p
e
n
r
e
x
u		 \$
6
0
0
5
7
5
-
~
A
i
i
i
t
c
q
u
s
o
n
s		 \$
1
5
0
2
5
0
-
~

Agenda

1. Business Update

2. Financials and Outlook

3. Midterm Strategy

4. Attachments

Expanded Global Presence Last 12 Months

* including clinics where FME has an interest of at least 10%

Dialysis Services Worldwide - Patients

North America

where FME has an interest of at least 10%

Source: Company data

Global Patients by Region

2007

Sustainable Patient Growth of ~ 6% p.a.

~ 2 million patients expected by 2010

~ 4 million patients expected by 2025

Source: Company estimates

Dialysis Products Worldwide

  • •We clearly gained market share in HD
  • •Produced 75 Million Dialyzers in 2007
  • •Produced the Company's 500 Millionth Dialyzer
  • •RSI Acquisition to set standards in future technologies

Source: 2007 Company data / internal estimates

New Products 2008/2009

© 2008 Fresenius Medical Care AG & Co. KGaA

2010 Revenue Target

Sustainable Growth of Earnings After Tax – Low to Mid-Teens per year

Our Growth Drivers

Targeted Revenue Growth in 2008 >7%

Thank You for your interest in Fresenius Medical Care !

Agenda

1. Business Update

2. Financials and Outlook

3. Midterm Strategy

4. Attachments

Dialysis Services - Global

H
2
0
0
8
1		 C
l
i
i
n
c		 P
i
t
t
a
e
n
s		 T
t
t
r
e
a
m
e
n
s
(
in
i
l
l
ion
)
m
T
l
t
o
a		 2
3
1
8
,		 1
7
9
3
4
0
,		 1
3
6
1
G
h
t
r
o
w		 5
%
+		 4
%
+		 5
%
+
N
h
A
i
t
o
r
m
e
r
c
a		 1
6
4
7
,		 1
2
3
7
8
4
,		 9
3
9
G
h
t
r
o
w		 4
%
+		 3
%
+		 3
%
+
I
i
l
t
t
n
e
r
n
a
o
n
a		 6
7
1		 5
5
5
5
6
,		 4
2
2
G
h
t
r
o
w		 7
%
+		 8
%
+		 8
%
+
E
r
o
p
e
u		 3
8
2		 2
8
7
9
9
,		 2
1
7
L
i
A
i
t
a
n
m
e
r
c
a		 1
7
5		 1
8
4
0
4
,		 1.
4
1
A
i
P
i
f
i
s
a-
a
c
c		 1
1
4		 8
3
5
3
,		 0.
6
4

H1 2008 – Strong Organic Growth

Total Revenue Increased 10% to \$ 5,177 m *

Dialysis Services - Global

Accelerated Growth Internationally of 16% cc

\$
U
S
i
i
l
l
i
n
m
o
n
s
-		 H
1
2
0
0
7		 H
1
2
0
0
8		 G
h
t
r
o
w		 c
c
N
h
A
i
t
o
r
m
e
r
c
a		 2
9
8
3
,		 3
0
2
8
,		 2
%
A
d
j
d
f
h
l
f
h
f
i
b
i
t
t
t
u
s
e
o
r
e
s
a
e
o
e
p
e
r
u
s
o
n
u
s
n
e
s
s		 3
%
I
i
l
t
t
n
e
r
n
a
o
n
a		 5
7
3		 7
4
1		 2
9
%		 1
6
%
T
l
t
o
a		 3
5
5
6
,		 3
6
9
7
,		 6
%		 4
%
A
d
j
d
f
h
l
f
h
f
i
b
i
t
t
t
u
s
e
o
r
e
s
a
e
o
e
p
e
r
u
s
o
n
u
s
n
e
s
s		 7
%		 5
%

cc = constant currency

Dialysis Products - Global

Excellent External Product Revenue Growth

\$
U
S
i
i
l
l
i
n
m
o
n
s
-		 H
1
2
0
0
7		 H
2
0
0
8
1		 G
h
t
r
o
w		 c
c
T
l
t
o
a
r
e
e
n
e
v
u
(
i
l.
I
l
R
)
t
n
c
n
e
r
n
a
e
v
e
n
u
e		 1
5
3
9
,		 8
2
2
1
,		 1
8
%		 1
0
%
E
l
t
e
r
n
a
r
e
e
n
e
x
v
u		 1
1
6
9
,		 0
8
1
4
,		 2
0
%		 1
1
%
N
h
A
i
t
o
r
m
e
r
c
a		 3
1
4		 3
5
4		 1
3
%		 1
3
%
I
i
l
t
t
n
e
r
n
a
o
n
a		 8
5
5		 0
1
5
4
,		 2
3
%		 1
0
%
C
h
F
l
a
s
o
w
\$
U
S
i
i
l
l
i
n
m
o
n
s
-		 H
1
2
0
0
7		 H
1
2
0
0
8		 G
h
t
r
o
w
1)
N
h
i
d
d
b
i
i
i
i
t
t
t
t
e
c
a
s
p
r
o
v
e
y
o
p
e
r
a
n
g
a
c
v
e
s		 5
0
8		 0
4
1
8
%
f r
o
ev
en		 (
)
2
1
%
ue
1)
C
i
l
d
i
t
t
(
)
a
p
a
e
x
p
e
n
u
r
e
s
t
n
e		 (
)
2
3
7		 (
3
3
2
)
F
C
h
F
l
r
e
e
a
s
o
w		 2
7
1		 6
9		 (
7
5
%
)
1)
A
i
i
i
f
d
i
i
t
t
t
t
c
q
u
s
o
n
s
n
e
o
v
e
s
u
r
e
s
,		 (
)
9
0		 (
9
2
)
F
C
h
F
l
r
e
e
a
s
o
w
f
i
i
i
t
t
a
e
r
a
c
q
s
o
n
s
u		 1
8
1		 (
)
2
3

1) A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

Profit & Loss

\$
S
U
i
i
l
l
i
n
m
o
n
s
-		 H
1
2
0
0
7		 H
2
0
0
8
1		 G
h
t
r
o
w
N
t
e
r
e
v
e
n
u
e		 4
7
2
5
,		 5
1
7
7
,		 *
1
0
%
O
i
i
(
E
B
I
T
)
t
p
e
r
a
n
g
n
c
o
m
e		 7
5
6		 8
8
1		 8
%
E
B
I
T
i
i
%
m
a
r
g
n
n		 1
6.
0		 8
1
5.
I
t
t
t
n
e
r
e
s
e
x
p
e
n
s
e
n
e
,		 1
8
7		 6
1
5
I
b
f
i
t
n
c
o
m
e
e
o
r
e
n
c
o
m
e
a
x		 5
6
9		 6
3
5		 1
5
%
I
T
n
c
o
m
e
a
e
p
e
n
s
e
x
x		 2
1
6		 2
3
4
T
t
a
r
a
e
x		 3
8
0
%		 3
7.
2
%
M
i
i
i
t
t
t
n
o
r
y
n
e
r
e
s		 1
4		 3
1
N
i
t
e
n
c
o
m
e		 3
3
9		 3
9
7		 1
7
%

* 6% growth at constant currency, 6% organic growth

EBIT margin

North America

Continued Solid Performance in All Segments

International

Days Sales Outstanding (DSO)

Overall Slightly Increasing since Beginning of the Year

Attachment I

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

E
l
R
t
e
r
n
a
e
e
n
e
x
v
u		 Q
2
2
0
0
8		 Q
2
2
0
0
7		 h
t
g
ro
w		 cc
In
io
l
du
te
t
t r
rn
a
na
p
ro
c
ev
en
ue		 6
3
8		 5
0
8		 2
6
%
+		 1
2
%
+
In
l re
te
rn
a
ve
nu
e
-		 (
7
9
)		 (
6
1
)
Ex
l r
te
rn
a
ev
en
ue
=		 5
5
9		 4
4
7		 2
5
%
+		 1
1
%
+
No
h
Am
ica
du
t
t r
r
er
p
ro
c
ev
en
ue		 3
1
5		 2
9
1		 8
%
+
In
l re
te
rn
a
ve
nu
e
-		 (
1
3
3
)		 (
1
3
0
)
Ex
l r
te
rn
a
ev
en
ue
=		 1
8
2		 1
6
1		 1
3
%
+
O
T
T
A
L
du
t r
p
ro
c
ev
en
ue		 9
5
3		 7
9
9		 1
9
%
+		 1
0
%
+
In
l re
te
rn
a
ve
nu
e
-		 (
)
2
1
2		 (
)
1
9
1
Ex
l r
te
rn
a
ev
en
ue
=		 7
4
1		 6
0
8		 2
2
%
+		 2
1
%
+
C
i
l
d
i
(
)
t
t
t
a
p
a
e
x
p
e
n
u
r
e
n
e		 H
1
2
0
0
8		 H
1
2
0
0
7		 Q
2
2
0
0
8		 Q
2
2
0
0
7
Pu
ha
f p
lan
d
ip
ty
t a
t
rc
se
o
ro
p
er
p
n
eq
m
en
u
,		 3
4
3		 2
4
9		 1
8
4		 1
3
3
Pr
ds
fro
le
f p
lan
d
ip
ty
t a
t
oc
ee
m
sa
o
ro
p
er
p
n
eq
u
m
en
-
,		 (
)
1
1		 (
2
)
1		 (
)
5		 (
3
)
Ca
i
l e
d
i
(
)
ta
tu
t
p
xp
en
re
ne
=		 3
3
2		 2
3
7		 1
7
9		 1
3
0

All numbers are in US-\$ millions

cc = constant currency

Attachment II

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

D
b
t
e		 Q
2
2
0
0
8		 F
Y
2
0
0
7		 F
Y
2
0
0
6		 F
Y
2
0
0
5		 F
Y
2
0
0
4
S
ho
bo
ing
t
te
r
rm
rro
w
s		 7
3
4		 2
1
7		 3
3
1		 1
5
1		 4
1
9
S
ho
bo
ing
fro
la
d p
ies
t
te
te
t
r
rm
rro
w
s
m
re
ar
+		 1
8
1		 2 5 1
9		 6
Cu
ion
f
lon
de
b
d c
i
l
lea
b
l
ig
ion
t p
t
te
t a
ta
t
rre
n
or
o
g-
rm
n
ap
se
o
a
s
+		 1
5
1		 8
5		 1
6
0		 1
2
6		 2
3
0
Cu
ion
f
Tr
Pr
fe
d
Se
i
ies
t p
t
t
t
rre
n
or
o
us
e
rre
cu
r
+		 - 6
0
7
Lo
de
b
d c
i
l
lea
b
l
ig
ion
les
ion
-te
t a
ta
t
t p
t
ng
rm
n
ap
se
o
a
s,
s c
ur
re
n
or
+		 8
3
4,
1		 0
0
4,
4		 3,
8
2
9		 0
7
7		 5
4
5
Se
Tr
Pr
fe
d
i
ies
(
f c
ion
)
t
t
t o
t p
t
us
e
rre
cu
r
ne
ur
re
n
or
+		 6
9
6		 6
6
4		 1,
2
5
4		 1,
1
8
8		 1,
2
7
9
T
l
d
b
t
t
o
a
e
=		 5,
9
4
5		 5,
6
4
2		 5,
5
7
9		 2,
1
9
1		 2,
4
7
9
E
B
I
T
D
A		 Q
2
2
0
0
8		 F
Y
2
0
0
7		 F
Y
2
0
0
6
(
p
ro
for
)
ma		 F
Y
2
0
0
5		 F
Y
2
0
0
4
La
lve
hs
ing
inc
(
E
B
I
T
)
t
tw
t
t
s
e
m
on
o
p
er
a
om
e		 6
2
1,
4		 8
0
1,
5		 3
6
1,
7		 9
3
9		 8
2
5
La
lve
hs
de
ia
ion
d a
iza
ion
t
tw
t
t
t
t
s
e
m
on
p
rec
an
mo
r
+		 3
9
2		 3
6
3		 3
2
6		 2
5
1		 2
3
3
No
h c
ha
n-c
as
rg
es
+		 4
2		 4
1		 3
5		 1
4		 1
3
E
B
I
T
D
A
(
l
ize
d
)
an
nu
a
=		 2,
0
7
6		 1,
9
8
4		 1,
7
2
8		 1,
2
0
4		 1,
0
9
8
C
h
F
l
a
s
o
w		 H
1
2
0
0
8		 H
1
2
0
0
7		 Q
2
2
0
0
8		 Q
2
2
0
0
7
Ac
is
i
ion
d
inv
d
ha
f
in
i
b
le
t
tm
ts
t p
ta
ts
q
u
s a
n
es
en
an
ne
ur
c
se
s o
ng
as
se		 (
1
3
3
)		 (
1
1
7
)		 (
6
0
)		 (
2
6
)
Pr
ds
fro
d
ive
i
t
tu
oc
ee
m
s
re
s		 4
1		 2
7		 2 2
8
Ac
is
i
io
f
d
ive
i
t
t o
t
tu
q
u
ns
ne
s
re
s
,		 (
9
2
)		 (
9
0
)		 (
5
8
)		 2

All numbers are in US-\$ millions

Contacts

Fresenius Medical Care AG & Co. KGaAInvestor RelationsElse-Kröner-Str. 161352 Bad Homburg v.d.H.

Ordinary sharesWKN 578 580ISIN DE0005785802SEDOL1 5129074 DE

Oliver MaierHead of Investor Relations & Corporate CommunicationsTel.: +49-(0)6172-609-2601Fax.: +49-(0)6172-609-2301Email: [email protected]

Terry L. MorrisTel.: +1-800-948-2538Fax.: +1-615-345-5605Email: [email protected]

Gerrit Jost

Tel.: +49-(0)6172-609-5216Fax.: +49-(0)6172-609-2301Email: [email protected]

Reminder …

November 4th, 2008 Report Q3/9M 2008

For further information and current news:www.fmc-ag.com

CalendarInvestor Relations > Financial Calendar

Annual Report / Quarterly Filings / SEC Filings / Deutsche Börse Filings ...Investor Relations > Publications

Corporate Governance / Sarbanes-Oxley Act / NYSE declaration ...Investor Relations > Corporate Governance

Financing / Analyst Coverage / Consensus estimates / Share data …Investor Relations > Our Share

More from Fresenius Medical Care AG & Co. KGaA

Regulatory Filings 2026
Jan 16
Share Issue/Capital Change 2026
Jan 12
Transaction in Own Shares 2026
Jan 9
Share Issue/Capital Change 2025
Dec 29
AGM Information 2025
Dec 22
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 15
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 12
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 8
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 3
Transaction in Own Shares 2025
Dec 1
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.